Chapter 3 Market Overview
- Market Definitions and Overview
- Risk Factors
- Symptoms
- Diagnosis
- Treatment and Therapy
- Blood Cancer Timeline (Milestones in Research)
- Product Approvals
- Screening and Prevention Programs
- Blood Cancer Awareness Month
- The Heroes Among Us Campaign
- Spot Leukemia Campaign
- Make Blood Cancer Visible Campaign
Chapter 4 Market Dynamics and Technology Background
- Market Drivers
- Rising Incidence of Blood Cancer
- Highly Sensitive Tests to Detect Minimal Residual Disease
- Rising Government and Private Funding for Cancer Treatment
- Challenges
- Absence of Screening Programs for Early Detection
- Low Awareness
Chapter 5 Market Breakdown by Disease Type
- Leukemia
- Lymphocytic Leukemias
- Myelogenous Leukemias
- Symptoms
- Causes
- Diagnosis
- Treatment
- Stages
- Treatment and Therapies
- Market Size and Analysis
- Acute Lymphoblastic Leukemia (ALL)
- Market Size and Analysis
- Acute Myeloid Leukemia (AML)
- Treatment and Therapies
- Market Size and Analysis
- Chronic Myeloid Leukemia (CML)
- Market Size and Analysis
- Chronic Lymphocytic Leukemia (CLL)
- First-Line Treatment Regimen
- Second-Line Treatment Regimen
- Market Size and Analysis
- Childhood Leukemia
- Non-Hodgkin Lymphoma
- Causes and Risk Factors
- Signs and Symptoms
- Diagnosis
- Staging
- Treatment
- Non-Hodgkin Lymphoma Treatment for Children, Adolescents and Young Adults
- Hodgkin Lymphoma
- Causes and Risk Factors
- Signs and Symptoms
- Diagnosis
- Staging
- Treatment
- Hodgkin Lymphoma Treatment for Children and Young Adults
- Lymphoma Therapeutics: Market Size and Analysis
- Multiple Myeloma
- Symptoms
- Causes and Risk Factors
- Treatment and Therapies
- Market Size and Analysis
- Hairy Cell Leukemia (HCL)
- Immunotherapy
Chapter 6 Blood Cancer Treatment Regimens
- Targeted Therapy
- B-Cell Leukemia/Lymphoma-2 (BCL-2) Inhibitors
- FLT3 Inhibitors
- Kinase Inhibitors
- IDH Inhibitors
- Proteasome Inhibitors
- Immunotherapy
- Monoclonal Antibodies (mAb) Therapy
- Chemotherapy
- DNA-Damaging Agents or Alkylating Agents
- Antitumor Antibiotics
- Antimetabolites
- DNA-Repair Enzyme Inhibitors
- Topoisomerase Inhibitors
- Drug Combination Therapies
- Leukemia
- Non-Hodgkin Lymphoma
- CAR-T Therapy
Chapter 7 Market Breakdown by Region
- North American Blood Cancer Therapeutic Market
- Epidemiology
- Market Size and Analysis
- European Blood Cancer Therapeutic Market
- Epidemiology
- Market Size and Analysis
- Asia-Pacific Blood Cancer Therapeutic Market
- Epidemiology
- Market Size and Analysis
- Rest of the World Blood Cancer Therapeutic Market
- Epidemiology
- Market Size and Analysis
Chapter 8 Pipeline Analysis
- Research and Development Overview
- Blood Cancer Drugs Under Development
- Promising Pipeline Molecules
- Venclexta (AbbVie Inc.)
- Empliciti (Bristol-Myers Squibb Co.)
- Aplidin (PharmaMar)
- SRF231 (Surface Oncology)
Chapter 9 Regulatory and Reimbursement Structure
- Overview of Regulations
- United States
- Canada
- Europe
- Japan
- China
- Overview of Pricing and Reimbursement
- United States
- Europe
- Japan
Chapter 10 Competitive Landscape and Key Developments
- Market Structure Analysis
- Patent Expiration for Blockbuster Drugs
- Key Industry Developments
Chapter 11 Company Profiles
- ABBVIE INC.
- Company Overview
- Product Information
- Development and Strategies
- Financials
- AMGEN INC.
- Product Information
- ASTRAZENECA PLC
- Company Overview
- Product Information
- Financials
- BOEHRINGER INGELHEIM PHARMACEUTICALS INC.
- Company Overview
- Financials
- Development and Strategies
- BRISTOL-MYERS SQUIBB CO.
- Company Overview
- Product Information
- Financials
- CELGENE CORP.
- Company Overview
- Product Information
- Financials
- GILEAD SCIENCES INC.
- Company Overview
- Financials
- GLAXOSMITHKLINE PLC
- Company Overview
- Development and Strategies
- Financials
- F. HOFFMANN-LA ROCHE LTD.
- Company Overview
- Product Information
- Financials
- JANSSEN GLOBAL SERVICES LLC
- Company Overview
- Financials
- MERCK & CO., INC.
- Company Overview
- Product Information
- Financials
- NOVARTIS AG
- Company Overview
- Product Information
- Financials
- PFIZER INC.
- Company Overview
- Product Information
- Financials
- TEVA PHARMACEUTICAL INDUSTRIES LTD.
- Company Overview
- Product Information
- Development and Strategies
- Financials
Chapter 12 Appendix: Acronyms and Glossary
- Acronyms
- Glossary of Terms
List of Tables
Summary Table: Global Market for Blood Cancer Therapeutics, by Disease Type, Through 2023
Table 1: Type of Blood Cancers (Hematological Cancer)
Table 2: Milestones in the History of Leukemia
Table 3: Product Approvals, 2016-2018
Table 4: Classification of Leukemia
Table 5: Types of Leukemia, Key Features, Occurrence
Table 6: Diagnostic Examination for Leukemia
Table 7: PCR Tests
Table 8: Additional Tests
Table 9: Treatments for Leukemia
Table 10: Newer Classes of Drugs
Table 11: Types of Stem Cell Transplantation
Table 12: Types of Targeted Therapies
Table 13: Types of Radiation Therapies
Table 14: Global Market for Leukemia Therapeutics, by Subtype, Through 2023
Table 15: Global Market for Leukemia Therapeutics, by Region, Through 2023
Table 16: Acute Lymphoblastic Leukemia (ALL) Treatment
Table 17: Therapies Approved for Acute Lymphoblastic Leukemia (ALL)
Table 18: Global Market for Acute Lymphocytic Leukemia (ALL) Therapeutics, by Region, Through 2023
Table 19: Therapies Approved for Acute Myeloid Leukemia
Table 20: Global Market for Acute Myeloid Leukemia Therapeutics, by Region, Through 2023
Table 21: Therapies Approved for Chronic Myeloid Leukemia
Table 22: Global Market for Chronic Myeloid Leukemia Therapeutics, by Region, Through 2023
Table 23: Therapies Approved for Chronic Lymphocytic Leukemia
Table 24: Global Market for Chronic Lymphocytic Leukemia Therapeutics, by Region, Through 2023
Table 25: Childhood Leukemia, Five-Year Relative Survival, Age 0-14, 1975-2014
Table 26: Childhood Leukemia, Five-Year Relative Survival, Age 0-19, 1975-2014
Table 27: Subtypes of Non-Hodgkin Lymphoma, by Type
Table 28: Non-Hodgkin Lymphoma, Stages and Modifying Features
Table 29: Drugs Approved for Non-Hodgkin Lymphoma
Table 30: Monoclonal Antibodies Approved for Non-Hodgkin Lymphoma
Table 31: Subtypes of Hodgkin Lymphoma, by Type
Table 32: Hodgkin Lymphoma, Stages and Modifying Features
Table 33: Therapies Approved for Classical Hodgkin Lymphoma
Table 34: Hodgkin Lymphoma, Annual Incidence Rates, 2011-2015
Table 35: Global Market for Lymphoma Therapeutics, by Region, Through 2023
Table 36: Effect of Treatment on Multiple Myeloma
Table 37: Therapies Approved for Multiple Myeloma
Table 38: Chemotherapy Drugs for Multiple Myeloma
Table 39: Effect of Treatment on Multiple Myeloma
Table 40: Global Market for Multiple Myeloma Therapeutics, by Region, Through 2023
Table 41: Drug Approved for Hairy Cell Leukemia
Table 42: Global Market for Blood Cancer Therapeutics, by Region, Through 2023
Table 43: North American Estimated Incidence of Blood Cancer, by Country, 2018
Table 44: North American Market for Blood Cancer Therapeutics, by Disease Type, Through 2023
Table 45: North American Market for Leukemia Therapeutics, by Subtype, 2017-2023
Table 46: North American Market for Blood Cancer Therapeutics, by Country, Through 2023
Table 47: European Estimated Incidence of Blood Cancer, by Country, 2018
Table 48: European Market for Blood Cancer Therapeutics, by Disease Type, Through 2023
Table 49: European Market for Leukemia Therapeutics, by Subtype, 2017-2023
Table 50: European Market for Blood Cancer Therapeutics, by Country, Through 2023
Table 51: Asia-Pacific Estimated Incidence of Blood Cancer, by Country, 2018
Table 52: Asia-Pacific Market for Blood Cancer Therapeutics, by Disease Type, Through 2023
Table 53: Asia-Pacific Market for Leukemia Therapeutics, by Subtype, Through 2023
Table 54: Asia-Pacific Market for Blood Cancer Therapeutics, by Country, Through 2023
Table 55: Rest of the World Estimated Incidence of Blood Cancer, by Country, 2018
Table 56: Rest of the World Market for Blood Cancer Therapeutics, by Disease Type, Through 2023
Table 57: Rest of the World Market for Leukemia Therapeutics, by Subtype, Through 2023
Table 58: Pipeline: Phase I, 2018
Table 59: Pipeline, Phase II, 2018
Table 60: Pipeline, Phase III, 2018
Table 61: Potential Drugs, Indication and Estimated Filing, 2018
Table 62: Patent Expiration of Blood Cancer Drugs
Table 63: Key Developments, 2016-2018
Table 64: AbbVie Inc.: Marketed Products
Table 65: AbbVie Inc.: Net Revenue, 2015-2017
Table 66: Amgen Inc.: Marketed Products
Table 67: AstraZeneca plc: Marketed Products
Table 68: AstraZeneca plc: Net Revenue, 2014-2017
Table 69: Boehringer Ingelheim GmbH: Net Revenue, 2015-2017
Table 70: Bristol-Myers Squibb Co.: Marketed Products
Table 71: Bristol-Myers Squibb Co.: Net Revenue, 2014-2016
Table 72: Celgene Corp.: Marketed Products
Table 73: Celgene Corp.: Net Revenue, 2015-2016
Table 74: Gilead Sciences Inc.: Net Revenue, 2014-2016
Table 75: GlaxoSmithKline plc: Net Revenue, 2014-2016
Table 76: F. Hoffmann-La Roche Ltd.: Marketed Products
Table 77: F. Hoffmann-La Roche Ltd.: Net Revenue, 2015-2017
Table 78: Johnson & Johnson Inc.: Net Revenue, 2014-2016
Table 79: Merck & Co., Inc.: Marketed Products
Table 80: Merck & Co., Inc.: Net Revenue, 2014-2016
Table 81: Novartis AG: Marketed Products
Table 82: Novartis AG: Net Revenue, 2014-2016
Table 83: Pfizer Inc.: Marketed Products by Indication
Table 84: Pfizer Inc.: Net Revenue, 2015-2017
Table 85: Teva Pharmaceutical Industries Ltd.: Marketed Products
Table 86: Teva Pharmaceutical Industries Ltd.: Net Revenue, 2015-2017
Table 87: Acronyms Used in This Blood Cancer Therapeutics Report
Table 88: Glossary of Terms Used in This Blood Cancer Therapeutics Report
List of Figures
Summary Figure: Global Market for Blood Cancer Therapeutics, by Disease Type, 2017-2023
Figure 1: Percentage Share of Global Blood Cancer Prevalence, 2018
Figure 2: Percentage Share of Cancer Incidence in the U.S., by Top 10 Cancer Types, 2018
Figure 3: U.S. Leukemia Statistics, by Annual Rates (per 100,000 Population) and Number of New Cases (Total Cases), 1999-2016
Figure 4: Awareness Campaigns
Figure 5: Types of Leukemia, Key Features, Occurrence
Figure 6: Global Market for Leukemia Therapeutics, 2017-2023
Figure 7: Global Market for Leukemia Therapeutics, by Subtype, 2017-2023
Figure 8: Global Market Share for Leukemia Therapeutics, by Subtype, 2018
Figure 9: Global Market Share for Leukemia Therapeutics, by Subtype, 2023
Figure 10: Global Market for Leukemia Therapeutics, by Region, 2017-2023
Figure 11: Global Market for Acute Lymphocytic Leukemia (ALL) Therapeutics, 2017-2023
Figure 12: Global Market for Acute Lymphocytic Leukemia (ALL) Therapeutics, by Region, 2017-2023
Figure 13: Global Market for Acute Myeloid Leukemia Therapeutics, 2017-2023
Figure 14: Global Market for Acute Myeloid Leukemia Therapeutics, by Region, 2017-2023
Figure 15: Global Market for Chronic Myeloid Leukemia Therapeutics, 2017-2023
Figure 16: Global Market for Chronic Myeloid Leukemia Therapeutics, by Region, 2017-2023
Figure 17: Global Market for Chronic Lymphocytic Leukemia Therapeutics, 2017-2023
Figure 18: Global Market for Chronic Lymphocytic Leukemia Therapeutics, by Region, 2017-2023
Figure 19: Global Market for Lymphoma Therapeutics, 2017-2023
Figure 20: Global Market for Lymphoma Therapeutics, by Region, 2017-2023
Figure 21: Global Market for Multiple Myeloma Therapeutics, 2017-2023
Figure 22: Global Market for Multiple Myeloma Therapeutics, by Region, 2017-2023
Figure 23: Global Market for Blood Cancer Therapeutics, 2017-2023
Figure 24: Global Market for Blood Cancer Therapeutics, by Region, 2017-2023
Figure 25: Percentage Share of North American Leukemia (Estimated) Incidence, by Country, 2018
Figure 26: Estimated Leukemia Incidence in the United States, by Type, 2016-2018
Figure 27: Percentage Share of Estimated Blood Cancer Incidence in Canada, 2016
Figure 28: Percentage Share of North American Non-Hodgkin Lymphoma Estimated Incidence, by Country, 2018
Figure 29: Percentage Share of North American Hodgkin Lymphoma Estimated Incidence, by Country, 2018
Figure 30: North American Market for Blood Cancer Therapeutics, 2017-2023
Figure 31: North American Market for Blood Cancer Therapeutics, by Disease Type, 2017-2023
Figure 32: North American Market for Leukemia Therapeutics, by Subtype, 2017-2023
Figure 33: North American Market for Blood Cancer Therapeutics, by Country, 2017-2023
Figure 34: U.K. Top 20 Common Causes of Cancer Death, by Country, 2016
Figure 35: European Market for Blood Cancer Therapeutics, 2017-2023
Figure 36: European Market for Blood Cancer Therapeutics, by Disease Type, 2017-2023
Figure 37: European Market for Leukemia Therapeutics, by Subtype, 2017-2023
Figure 38: European Market for Blood Cancer Therapeutics, by Country, 2017-2023
Figure 39: Asia-Pacific Market for Blood Cancer Therapeutics, 2017-2023
Figure 40: Asia-Pacific Market for Blood Cancer Therapeutics, by Disease Type, 2017-2023
Figure 41: Asia-Pacific Market for Leukemia Therapeutics, by Subtype, 2017-2023
Figure 42: Asia-Pacific Market for Blood Cancer Therapeutics, by Country, 2017-2023
Figure 43: Rest of the World Market for Blood Cancer Therapeutics, 2017-2023
Figure 44: Rest of the World Market for Blood Cancer Therapeutics, by Disease Type, 2017-2023
Figure 45: Rest of the World Market for Leukemia Therapeutics, by Subtype, 2017-2023
Figure 46: Federal and Inter-provincial Approval System for Cancer Drugs in Canada
Figure 47: AbbVie Inc.: Revenue Share, by Country, 2017
Figure 48: Boehringer Ingelheim GmbH: Revenue Share, by Region, 2017
Figure 49: Boehringer Ingelheim GmbH: Revenue Share, by Business Segment, 2017
Figure 50: Boehringer Ingelheim GmbH: R&D Expenditures, 2015-2017
Figure 51: Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, 2017
Figure 52: Gilead Sciences Inc.: Revenue Share, by Business Segment, 2016
Figure 53: Gilead Sciences Inc.: Revenue Share, by Country/Region, 2016
Figure 54: GlaxoSmithKline plc: Revenue Share, by Business Segment, 2016
Figure 55: GlaxoSmithKline plc: Revenue Share, by Region, 2016
Figure 56: F. Hoffmann-La Roche Ltd.: Revenue Share, by Segment, 2017
Figure 57: F. Hoffmann-La Roche Ltd.: Revenue Share, by Region, 2017
Figure 58: Johnson & Johnson Inc.: Revenue Share, by Business Segment, 2016
Figure 59: Johnson & Johnson Inc.: Revenue Share, by Country/Region, 2016
Figure 60: Merck & Co., Inc.: Revenue Share, by Business Segment, 2016
Figure 61: Merck & Co., Inc.: Revenue Share, by Country/Region, 2016
Figure 62: Novartis AG: Revenue Share, by Country/Region, 2016
Figure 63: Novartis AG: Revenue Share, by Business Segment, 2016
Figure 64: Pfizer Inc.: Revenue Share, by Country/Region, 2016
Figure 65: Pfizer Inc.: Revenue Share, by Business Segment, 2016
Figure 66: Teva Pharmaceutical Industries Ltd.: Revenue Share, by Region, 2017
Figure 67: Teva Pharmaceutical Industries Ltd.: Revenue Share, by Business Segment, 2016
